Evidence deep dives for Protein-Losing Nephropathy
Pair mechanism-level evidence with practical protocol context before discussing next steps with your veterinarian.
When the Kidneys Leak What the Body Cannot Afford to Lose
Protein-losing nephropathy (PLN) is a kidney disease in which the glomeruli — the microscopic filtering units of the kidneys — become damaged and lose their ability to retain protein in the blood. In a healthy kidney, the glomerular barrier is exquisitely selective: it allows water and small waste molecules to pass into the urine while keeping proteins (particularly albumin) in the bloodstream. When this barrier breaks down, protein pours into the urine at rates that overwhelm the body’s ability to compensate.
The consequences cascade rapidly. As albumin drops in the blood (hypoalbuminemia), the oncotic pressure that holds fluid inside blood vessels falls. Fluid leaks into tissues, causing edema — swelling of the limbs, face, and abdomen. The liver ramps up protein production to compensate, but it also increases clotting factor production, creating a dangerous hypercoagulable state. Blood clots become one of the most feared complications of PLN, capable of blocking blood vessels in the lungs (pulmonary thromboembolism), brain, or kidneys themselves.
PLN is not a single disease. It is a clinical syndrome with multiple possible underlying causes, including immune-mediated glomerulonephritis, amyloidosis, and breed-specific genetic nephropathies. Identifying the specific cause matters because it guides treatment and defines prognosis.
Breeds at Elevated Risk
Several breeds carry documented genetic predispositions to PLN:
Soft-Coated Wheaten Terrier: The most well-characterized breed-specific PLN. A genetic association with NPHS1 and KIRREL2 genes has been identified. Wheatens may also develop concurrent protein-losing enteropathy (PLE), a condition in which protein is lost through the intestinal tract as well. The combination of PLN and PLE in this breed is devastating and often presents simultaneously.
Bernese Mountain Dog: A hereditary glomerulonephritis is well-documented, with a genetic basis involving immune-mediated mechanisms. Clinical presentation typically occurs between 2-7 years of age.
Miniature Schnauzer: Increased prevalence of glomerular disease compared to the general dog population.
Labrador Retriever, Golden Retriever: Overrepresented in PLN case series, though the genetic basis is less clearly defined than in Wheatens or Bernese.
Airedale Terrier: Historical breed association with renal amyloidosis, a specific form of PLN.
Genetic testing for PLN susceptibility is available for Soft-Coated Wheaten Terriers and should be part of routine breeding pair evaluation.
How PLN Damages the Body
The glomerulus is a network of capillaries surrounded by specialized cells (podocytes) and a basement membrane that together form the glomerular filtration barrier. This barrier has both size-selective and charge-selective properties: it blocks large molecules like albumin while freely filtering small molecules like creatinine and urea.
In PLN, the filtration barrier is damaged by one of several mechanisms:
Immune-mediated glomerulonephritis: Immune complexes deposit within the glomerulus (similar to the mechanism in systemic lupus erythematosus), triggering complement activation and inflammation that damages the filtration barrier. This is the most common mechanism in most breeds.
Amyloidosis: Abnormal protein fibrils (amyloid) deposit in the glomerulus, physically disrupting the filtration barrier. Amyloid deposits are not reversible and carry a particularly poor prognosis.
Focal segmental glomerulosclerosis (FSGS): Scarring of portions of the glomerulus, often progressive.
Regardless of the specific mechanism, the downstream consequences are the same:
- Massive proteinuria (urinary protein loss)
- Hypoalbuminemia (low blood albumin)
- Edema and third-space fluid accumulation (ascites, pleural effusion)
- Hypercoagulability and thromboembolism risk
- Progressive kidney damage leading to chronic kidney disease
- Hypertension (elevated blood pressure)
Clinical Signs
PLN often progresses silently until protein loss is severe enough to cause visible consequences. By the time clinical signs appear, the disease is typically advanced.
Early signs (often detected only by screening):
- Proteinuria on routine urinalysis (the earliest detectable abnormality)
- No visible clinical signs — the dog appears completely normal
- Mildly elevated urine protein:creatinine ratio (UPC) on screening bloodwork
Moderate disease:
- Increased thirst and urination
- Subtle weight loss or decreased muscle condition
- Decreased appetite
- Mild lethargy
Advanced disease (nephrotic syndrome):
- Peripheral edema: swelling of the limbs, particularly the hind legs
- Abdominal distension from ascites (fluid accumulation)
- Facial swelling, particularly around the eyes
- Respiratory difficulty if pleural effusion develops
- Severe lethargy and weakness
- Vomiting and diarrhea (uremia if kidney failure is progressing)
Thromboembolic complications (the most dangerous acute presentation):
- Sudden onset of severe respiratory distress (pulmonary thromboembolism)
- Acute hind limb weakness or paralysis (aortic thromboembolism)
- Sudden collapse
- Acute worsening of kidney function
Diagnostic Workup
Urine protein:creatinine ratio (UPC): The single most important screening and monitoring test. UPC quantifies protein loss relative to urine concentration, providing a standardized measure.
- UPC less than 0.5: normal
- UPC 0.5-2.0: borderline to mild proteinuria (warrants investigation)
- UPC above 2.0: significant proteinuria consistent with glomerular disease
- UPC above 3.5: severe proteinuria, high risk for nephrotic syndrome
Complete bloodwork:
- Chemistry panel: serum albumin (low), cholesterol (often elevated — the liver increases lipid production as part of the compensatory response), BUN and creatinine (elevated if kidney failure is concurrent)
- CBC: may be unremarkable or show anemia in advanced kidney disease
Blood pressure measurement: Hypertension is common in PLN and contributes to ongoing glomerular damage if not controlled.
Urinalysis with culture: Rules out urinary tract infection as a cause of proteinuria.
Infectious disease screening: Lyme disease, ehrlichiosis, heartworm disease, and leptospirosis can all cause immune-mediated glomerulonephritis. Identifying and treating an infectious trigger can slow or resolve the glomerular damage.
Kidney biopsy: The definitive diagnostic tool for identifying the specific type of glomerular disease. Biopsy results guide treatment decisions and provide prognostic information. Techniques include percutaneous ultrasound-guided biopsy and laparoscopic biopsy. Biopsy carries procedural risk (hemorrhage) and is typically reserved for cases where the result will change management.
Treatment
PLN treatment targets multiple fronts simultaneously: reducing protein loss, managing complications, treating the underlying cause, and protecting remaining kidney function.
Anti-proteinuric therapy:
- ACE inhibitors (enalapril, benazepril) or ARBs (telmisartan): Reduce glomerular capillary pressure and proteinuria. First-line therapy for all PLN cases. Combination ACE inhibitor + ARB may be used in refractory cases.
- Target: Reduce UPC by at least 50%, ideally below 2.0.
Immunosuppressive therapy (for immune-mediated glomerulonephritis):
- Mycophenolate mofetil: Increasingly favored as a first-line immunosuppressive for canine GN
- Prednisone/prednisolone: Used cautiously; corticosteroids can worsen proteinuria and increase thromboembolism risk
- Chlorambucil or cyclophosphamide: For severe or refractory cases
Anti-thrombotic therapy:
- Low-dose aspirin or clopidogrel: Used when albumin drops below 2.0 g/dL to reduce the risk of thromboembolism. Some internists begin anti-thrombotic therapy at albumin below 2.5 g/dL.
- The hypercoagulable state of PLN is one of the most dangerous acute complications and justifies proactive anti-clotting therapy.
Blood pressure control:
- Amlodipine: Added if ACE inhibitors alone do not normalize blood pressure
- Target: Systolic blood pressure below 160 mmHg
Dietary modification:
- Moderate protein restriction to reduce glomerular workload (consult veterinarian or veterinary nutritionist for specific formulation)
- Omega-3 fatty acid supplementation (shown to modestly reduce proteinuria and have anti-inflammatory effects on glomeruli)
- Moderate sodium restriction
Treatment of underlying cause:
- Infectious triggers: appropriate antimicrobial therapy (doxycycline for Lyme/ehrlichiosis, heartworm treatment, etc.)
- Neoplasia-associated: treatment of underlying cancer
12-Week Treatment and Monitoring Plan
- Weeks 1-2 (initiation): Baseline UPC, CBC, chemistry, blood pressure. Start ACE inhibitor. Begin anti-thrombotic therapy if albumin is below 2.0-2.5 g/dL. Consider kidney biopsy if it will change management.
- Weeks 3-4 (response check): Recheck UPC, albumin, creatinine. Assess blood pressure. If UPC has not improved, increase ACE inhibitor dose or add ARB.
- Weeks 5-6 (treatment escalation if needed): If immune-mediated GN is confirmed or suspected, initiate immunosuppressive therapy. Recheck bloodwork. Adjust dietary protein.
- Weeks 7-8 (complication monitoring): Monitor for edema, respiratory changes (thromboembolism), and appetite. Recheck UPC and albumin.
- Weeks 9-10 (treatment optimization): Evaluate the cumulative treatment response. Stable or declining UPC with rising albumin indicates effective therapy. Worsening values despite treatment suggest a guarded prognosis.
- Weeks 11-12 (long-term planning): Establish the monitoring cadence (UPC and bloodwork every 4-8 weeks initially, then every 2-3 months once stable). Document the effective medication regimen.
Feeding and Nutritional Considerations
Diet is an important component of PLN management:
- Moderate protein restriction under veterinary guidance (excessive restriction causes muscle wasting; insufficient restriction increases proteinuria)
- Omega-3 fatty acid supplementation from marine sources (EPA/DHA)
- Moderate sodium restriction
- Adequate caloric intake to prevent catabolism
For detailed guidance:
- Feeding Guide for Adult Dogs: Maintenance Nutrition Without Drift
- Omega-3 Fish Oil for Dogs: Evidence, Dosing Context, and Safety
- Prescription Diets for Dogs: Evidence, Use Cases, and Limits — renal-specific diets with controlled protein and phosphorus levels are relevant when PLN progresses to chronic kidney disease
When to Go to the ER Today
- Sudden severe respiratory distress (possible pulmonary thromboembolism)
- Acute hind limb weakness or paralysis (possible aortic thromboembolism)
- Rapid abdominal distension with difficulty breathing
- Collapse or sudden weakness
- Persistent vomiting with inability to keep down food or water
- Severely swollen limbs with pain
- Complete appetite refusal with progressive decline
Thromboembolic events are the most acute life-threatening complication of PLN. Any sudden-onset respiratory distress or limb dysfunction in a dog with known PLN requires immediate emergency care.
Related Condition Pathways
- Kidney Disease: PLN can progress to chronic kidney disease
- Chronic Kidney Disease Staging: IRIS staging guides management as kidney function declines
- Protein-Losing Enteropathy: Can occur concurrently with PLN, especially in Soft-Coated Wheaten Terriers
- Lyme Disease: A recognized infectious trigger for immune-mediated glomerulonephritis
- Systemic Lupus Erythematosus: SLE is a cause of immune-complex glomerulonephritis
Related Breed Longevity Guides
- Soft-Coated Wheaten Terrier Lifespan & Longevity Guide
- Bernese Mountain Dog Lifespan & Longevity Guide
- Miniature Schnauzer Lifespan & Longevity Guide
- Labrador Retriever Lifespan & Longevity Guide
- Golden Retriever Lifespan & Longevity Guide
- Airedale Terrier Lifespan & Longevity Guide
Related Evidence and Research
- Chronic Kidney Disease Staging in Dogs: The IRIS Protocol
- Urinalysis for Early Kidney Detection
- Blood Pressure Monitoring in Dogs
Frequently Asked Questions
Is PLN curable?
In cases where an infectious trigger (Lyme disease, ehrlichiosis) is identified and treated, the glomerular disease may resolve or stabilize. In breed-specific genetic forms (Soft-Coated Wheaten Terrier, Bernese Mountain Dog) or idiopathic immune-mediated forms, PLN is typically managed rather than cured. Long-term prognosis varies from months to years depending on disease severity and treatment response.
What does the genetic test for Wheatens tell me?
The PLN genetic test for Soft-Coated Wheaten Terriers identifies risk alleles associated with the disease. Dogs homozygous for risk alleles are at highest risk. However, not all genetically at-risk dogs develop clinical PLN, and environmental or other genetic factors likely play a role. The test is most useful for breeding decisions and for identifying dogs that need enhanced monitoring.
Can PLN cause blood clots?
Yes. Thromboembolism is one of the most feared complications of PLN. When albumin drops below approximately 2.0 g/dL, the risk of clot formation increases substantially due to loss of antithrombin and other anti-coagulant proteins in the urine, combined with increased hepatic production of pro-coagulant factors. This is why anti-thrombotic therapy is started proactively.
How often should my dog be monitored?
During active treatment adjustment: every 2-4 weeks. Once stable: every 2-3 months. UPC, serum albumin, creatinine, and blood pressure are the core monitoring parameters. Any clinical change (increased drinking, decreased appetite, swelling) warrants earlier rechecking.
Should I restrict my dog’s protein intake?
Moderate protein restriction is generally recommended under veterinary guidance. The goal is to reduce the protein load on damaged glomeruli without causing malnutrition or muscle wasting. A veterinary nutritionist can formulate a diet that balances these competing needs based on your dog’s specific UPC and albumin levels.
Medical Disclaimer
This content is educational and does not replace veterinary diagnosis or treatment. Dogs with excessive urination, swelling, unexplained weight loss, or sudden breathing difficulty need prompt veterinary evaluation including urine protein assessment.
References
- Littman MP et al. Familial protein-losing enteropathy and protein-losing nephropathy in Soft Coated Wheaten Terriers: 222 cases (1983-1997). J Vet Intern Med. 2000;14(1):68-80.
- Goldstein RE et al. Urinary protein:creatinine ratio and clinical outcome of naturally occurring canine glomerular disease. J Am Vet Med Assoc. 2013;243(9):1285-1293.
- IRIS (International Renal Interest Society). IRIS staging of CKD and glomerular disease guidelines. iris-kidney.com.
- Schneider SM et al. Prevalence of immune-complex glomerulonephritis in dogs biopsied for suspected glomerular disease: 501 cases (2007-2012). J Vet Intern Med. 2013;27(S1):S67-S75.
- Vaden SL. Glomerular disease. Top Companion Anim Med. 2011;26(3):128-134.
Related reads
Related Reading
Continue exploring
